| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 421 | 384 |
| Net (decrease) increase in cash and cash equivalents | -7,475 | -2,860 |
| Cash and cash equivalents at beginning of period | 22,563 | - |
| Cash and cash equivalents at end of period | 15,088 | - |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)